NCT02994784 · OUTCOME

Platelet Engraftment

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients · Source last updated 2023-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: 100 days

What was measured

Assess time to platelet engraftment

Groups in this outcome

Evomela

Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation Propylene Glycol-Free Melphalan Hydrochloride: Intravenous Propylene Glycol-Free Melphalan Hydrochloride

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Evomela	27

Reported measurements

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Evomela	17	Not reported	14	27	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
14
upper Limit
27
value
17

denoms

counts
group Id
OG000
value
27
units
Participants

description

Assess time to platelet engraftment

dispersion Type

Full Range

groups

description
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) administered intravenously at 70-100 mg/m2/day on Days -3 and -2 prior to autologous stem cell transplantation Propylene Glycol-Free Melphalan Hydrochloride: Intravenous Propylene Glycol-Free Melphalan Hydrochloride
id
OG000
title
Evomela

param Type

MEDIAN

reporting Status

POSTED

time Frame

100 days

title

Platelet Engraftment

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice